TICKERNERD
Menu
SRPTSRPTHealthcare · Biotechnology

SRPT Stock Forecast: Sarepta Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$17
+1.94% on the day

The 24 Wall Street analysts covering Sarepta Therapeutics, Inc. hold a median 12-month price target of $20 — +18.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 14 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
73 / 100
Median analyst target
$20
Analysts covering
24
Revenue$401.3M−34.3% y/y
Operating income$52.3M
Net income−$4.9M
Free cash flow$196.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−19.6%
YTD
−21.8%
1Y
−21.5%
From 52W high
−31.2%
From 52W low
+13.3%
$15
$24
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SRPT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Sarepta Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
73 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Accruals
93
Quality
81
Issuance
77
Volatility
52
Momentum
43
Revisions
41
Size
36
Growth
27

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (27): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SRPT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SRPT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Jan 26Apr 26Jul 26Oct 26SRPTHigh $38Median $20Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says24 analysts
7 Buy12 Hold5 Sell
Low $5Median $20High $38

The green dot is the last close — the median target sits +18.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
8 Oct 2026RBC CapitalMaintainsSector Perform$19 → $17
5 Oct 2026HC Wainwright & Co.ReiteratesSell$5.00
30 Sept 2026JP MorganMaintainsNeutral—
30 Sept 2026JP MorganMaintainsNeutral$23 → $20
28 Sept 2026NeedhamReiteratesUnderperform—
28 Sept 2026NeedhamReiteratesUnderperform—
9 July 2026Piper SandlerMaintainsNeutral$23 → $20
9 July 2026Piper SandlerMaintainsNeutral—
9 July 2026Wolfe ResearchUpgradeOutperform$27
9 July 2026Wolfe ResearchUpgradeOutperform—
16 Apr 2026HC Wainwright & Co.ReiteratesSell—
26 Mar 2026CitigroupMaintainsSell—
26 Mar 2026NeedhamReiteratesUnderperform—
19 Mar 2026OppenheimerReiteratesOutperform—
13 Mar 2026MizuhoMaintainsOutperform—
10 Mar 2026CitigroupMaintainsSell—
2 Mar 2026HC Wainwright & Co.ReiteratesSell—
27 Feb 2026Wells FargoMaintainsOverweight—
27 Jan 2026HC Wainwright & Co.ReiteratesSell—
23 Jan 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SRPT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SRPT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Sarepta Therapeutics, Inc. returned −21.5% against +17.5% for the S&P 500, dividends included.

SRPT vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26SRPTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SRPT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−10.3%
Analysts raising
0
Analysts cutting
1
Fundamentals

Sarepta Therapeutics, Inc. (SRPT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
45.5×

Cheaper than 16% of US stocks

Price / sales
0.9×

Cheaper than 70% of US stocks

Price / book
1.2×

Cheaper than 66% of US stocks

EV / EBITDA
−117.0×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
−34.3%

Higher than 8% of US stocks

Earnings growth (YoY)
−34.3%

Higher than 15% of US stocks

Gross margin
62.8%

Higher than 76% of US stocks

Operating margin
13.0%

Higher than 70% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−9.5%

Higher than 36% of US stocks

Return on assets
−1.1%

Higher than 39% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Sarepta Therapeutics, Inc. (SRPT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sarepta Therapeutics, Inc. has a market value of $1.8B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter shrank 34.3% year on year.

  • Net income over the same four quarters: −$136.7M, a −6.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.90.

  • Free cash flow in the twelve months to 30 June 2026: $75.0M.

  • Shares outstanding: 105.6M.

  • Trailing P/E: 45.5×; forward P/E: 7.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Sarepta Therapeutics, Inc. employs 835 people — $2.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

SRPT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SRPTSarepta Therapeutics, Inc.$1.8B
73
ZYMEZymeworks, Inc.$1.8B
58
VIRVir Biotechnology, Inc.$1.8B
92
PVLAPalvella Therapeutics, Inc.$1.8B
30
URGNUroGen Pharma Ltd.$1.8B
83
BRVEBraveheart Bio, Inc.$1.7B
0
XNCRXencor, Inc.$1.7B
84

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Sarepta Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SRPT news & analysis

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Business Wire · 14 Oct 2026positive

Sarepta presented preclinical data at the Oligonucleotide Therapeutics Society annual meeting showing that investigational siRNA program SRP-1003 can reduce pathogenic DMPK transcripts in the nucleus in DM1.

Why it matters — The findings concern SRP-1003’s preclinical activity against a molecular driver of DM1, an area relevant to Sarepta’s development program.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Business Wire · 5 Oct 2026negative

The law firm Kahn Swick & Foti announced it has commenced an investigation into the officers and directors of Sarepta Therapeutics. The firm, led by former Louisiana Attorney General Charles C. Foti Jr., is examining the biopharmaceutical company, whose most important product is Elevidys for Duchenne muscular dystrophy.

Why it matters — An investigation into Sarepta's officers and directors could signal potential legal or governance concerns for SRPT shareholders.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 30 Sept 2026neutral

Sarepta Therapeutics granted equity awards on Sept. 30, 2026, under its 2024 Employment Commencement Incentive Plan, which were approved by the Compensation Committee as a material inducement to employment for 37 individuals hired in the third quarter of 2026. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — The announcement reflects Sarepta's continued hiring and use of equity incentive grants to attract new employees, which could be of interest to shareholders monitoring the company's workforce and compensation practices.

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne

Business Wire · 30 Sept 2026positive

Sarepta presented new data at the 31st Annual Congress of the World Muscle Society providing evidence of clinically meaningful functional benefit of ELEVIDYS in older ambulatory patients with Duchenne muscular dystrophy, specifically those treated at ages 8 to 12. The data also demonstrated safety of the therapy in this patient group.

Why it matters — SRPT watchers would care because this new clinical data supports the safety and functional benefit of ELEVIDYS in older ambulatory patients, potentially broadening the therapy's clinical evidence base in a patient population where functional decline is a growing concern.

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Business Wire · 25 Sept 2026positive

Sarepta Therapeutics announced it will present new data from its Duchenne muscular dystrophy treatment portfolio at the 31st Annual Congress of the World Muscle Society, to be held Sept. 29 - Oct. 3 in Hiroshima, Japan. The presentations include a late-breaking poster on the efficacy and safety of delandistrogene moxeparvovec in older, ambulatory Duchenne patients.

Why it matters — A SRPT watcher would care because the presentation of new efficacy and safety data on its Duchenne gene therapy at a major scientific congress could offer insight into the treatment's performance in an additional patient population.

FAQ

Frequently asked questions about SRPT stock

What is the SRPT stock price forecast for 2026-2027?

The 24 Wall Street analysts covering Sarepta Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SRPT stock a buy right now?

Of the 24 analysts covering Sarepta Therapeutics, Inc., 7 rate it a Buy, 12 a Hold and 5 a Sell. Ticker Nerd's systematic factor model ranks Sarepta Therapeutics, Inc. 73 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SRPT?

As at 14 Oct 2026, Sarepta Therapeutics, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will SRPT stock go up?

No one can know that. What the data says: the median 12-month target from 24 analysts implies +18.8% from the last close, and Ticker Nerd's factor model ranks Sarepta Therapeutics, Inc. 73 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SRPT stock forecast for 2030?

No analyst covering Sarepta Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRPT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.

How has SRPT stock performed over the past year?

Sarepta Therapeutics, Inc. returned -21.5% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sarepta Therapeutics, Inc. do?

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders.

What is the latest news on SRPT?

The most recent item we track (Business Wire, 14 Oct 2026): "Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting". Sarepta presented preclinical data at the Oligonucleotide Therapeutics Society annual meeting showing that investigational siRNA program SRP-1003 can reduce pathogenic DMPK transcripts in the nucleus in DM1.

Company

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based treatments, gene therapies, and other genetic medicine modalities designed to address underlying disease mechanisms. Its current portfolio includes approved and commercialized therapies for Duchenne muscular dystrophy, along with additional programs in development for other rare genetic conditions. Sarepta Therapeutics also maintains a broader research and manufacturing platform centered on advancing genetic medicine from discovery through delivery. Based in Cambridge, Massachusetts, the company plays a notable role in the rare disease market by combining therapeutic innovation with a specialized focus on patients who often have limited treatment options.

CEO Dr. Michael E. Severino M.D. · 835 employees · United States · https://www.sarepta.com